A Phase 4 interventional study of Enteric Coated Aspirin Tablet and Plain Aspirin in Stroke, Ischemic, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-02.
Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing aspirin in Ischemic Stroke — 6 open to participants now, 6 under way, 2 of them phase 3. Aspirin · Ischemic Stroke.
Among the 22 studies testing aspirin in Ischemic Stroke, this one is the 17th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 4, and was the 11th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →6 of the 22 studies testing aspirin in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:
Capital Medical University · Sites in China
Ages 18+
Rajaie Cardiovascular Medical and Research Center · Sites in Iran, Islamic Republic of
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Sichuan Provincial People's Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 350 across the 22 interventional studies. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 22 have an industry lead sponsor. The 10 most frequent:
Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Hamad Medical Corporation has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies testing aspirin in Ischemic Stroke that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT05910125Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing aspirin in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced Thromboxane A2 (TXA 2) levels in diabetic patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4-Patients with ischemic stroke who underwent reperfusion intervention (catheter-directed thrombolysis and/or thrombectomy) regardless of the time of presentation (i.e within or outside the therapeutic window as the managing stroke deem fit.
Exclusion Criteria:
EC aspirin loading dose 300mg followed by 100 mg (2 days). The study's total duration is 3 days.
Drug: Enteric Coated Aspirin Tablet
Dispersible Aspirin loading dose 300mg followed by 75mg tablets (2 days) The study's total duration is 3 days.
Drug: Plain Aspirin
Study participants will be assigned to receive either EC Aspirin and will be required to continue taking them throughout the study (three days).
Study participants will be assigned to receive either Plain Aspirin and will be required to continue taking them throughout the study (three days).
Incidence of Aspirin non-responders.
Aspirin nonresponsiveness is defined as a level of residual serum TXB2 associated with elevated thrombotic risk (\<99.0% inhibition or TXB2 \>3.1 ng/ml) after 3 daily aspirin doses
Time frame: At "Day 3"
Incidence of Gastrointestinal bleeding consequent upon aspirin therapy.
Major and minor GIT bleeding
Time frame: After three daily aspirin doses ( at "Day 3")
Ran from Aug 2019 to primary completion in Jan 2020, 4 months.
Of 85 phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin